Journal of Controlled Release最新文献

{"title":"A cGAS-STING pathway activating cobalt(III) cyclam prodrug for combined chemotherapy and immunotherapy of breast cancer","authors":"Haiqin Song ,&nbsp;Nicolás Montesdeoca ,&nbsp;Elizaveta Efanova ,&nbsp;Xuan Li ,&nbsp;Johannes Karges ,&nbsp;Haihua Xiao ,&nbsp;Kun Shang ,&nbsp;Hanchen Zhang","doi":"10.1016/j.jconrel.2025.113942","DOIUrl":"10.1016/j.jconrel.2025.113942","url":null,"abstract":"<div><div>Immunotherapy has had a tremendous impact on cancer treatments. Although frequently used inside the clinics, the application of immunomodulating compounds remains restricted due to the immunosuppressive tumor microenvironment. Among the promising methods, the activation of the stimulator of interferon genes (STING) pathway has emerged as a next-generation immunotherapeutic target. Despite promising preliminary results, the application of STING activating agents is strongly limited due to poor tumor selectivity and poor bioavailability. To overcome these limitations, herein, the first example of a cobalt(III) cyclam prodrug capable of inducing a chemotherapeutic effect and activating the STING pathway is reported. The cobalt(III) complex was found to be stable under physiological conditions, but released its axial ligands within the reducing cancerous microenvironment. While the reduced metal complex triggered a strong cytotoxic response by chemotherapy, the released organic ligands induced a strong immune response using the STING pathway, resulting in a multimodal treatment. To further enhance the pharmacological properties and provide tumor selectivity, the metal complex was encapsulated in polymeric nanoparticles. Upon injection into the blood stream, the nanoparticles accumulated in the triple-negative breast cancer tumor of the mouse model, activated the immune response inside the animal, and caused a nearly complete eradication of the tumor.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"384 ","pages":"Article 113942"},"PeriodicalIF":10.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144252605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “‘Biomimetic reactive oxygen/nitrogen nanoscavengers inhibit ‘ferroptosis storm’ and modulate immune targeting for acute kidney injury” [Journal of Controlled Release 379 (2025) 59–76]","authors":"Yuxin Cao ,&nbsp;Xiaowei Liu ,&nbsp;Chunjing Guo ,&nbsp;Weili Yang ,&nbsp;Xuemei Wang ,&nbsp;Xinxin Wang ,&nbsp;Haiyu Xu ,&nbsp;Wenming Wang ,&nbsp;Dandan Liu ,&nbsp;Jingwen Zhang ,&nbsp;Wenhao Cui ,&nbsp;Yuxiu Chen ,&nbsp;Xuan Guo ,&nbsp;Daquan Chen","doi":"10.1016/j.jconrel.2025.113918","DOIUrl":"10.1016/j.jconrel.2025.113918","url":null,"abstract":"","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"384 ","pages":"Article 113918"},"PeriodicalIF":10.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144238142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-assembled copper chlorogenic acid nanoparticles: Inducing pyroptosis and cuproptosis to activate antitumor immunity","authors":"Yuxin Zhou ,&nbsp;Qian Wang ,&nbsp;Qian Wang ,&nbsp;Ziyi Zhou ,&nbsp;Xiaoyang Peng ,&nbsp;Botao Qu ,&nbsp;Ruiping Zhang","doi":"10.1016/j.jconrel.2025.113941","DOIUrl":"10.1016/j.jconrel.2025.113941","url":null,"abstract":"<div><div>Currently, the tumor treatment faces many challenges. Although chemotherapy is the most effective and economical choice, most chemotherapy drugs lack tumor specificity, have low bioavailability, and face many obstacles in clinical application. Significantly, the tumor immunosuppressive microenvironment (TIME) and low immunogenicity in solid tumors also seriously affect the clinical effect of tumor therapy. Here, metal-phenolic network nanoparticles self-assembled by copper-coordinated natural drug chlorogenic acid (ChA) (ChA-Cu NPs) are designed to amplify cell immunogenic death mediated by cuproptosis and pyroptosis for antitumor immunotherapy. Specifically, the synthesized ChA-Cu NPs can disintegrate and release Cu²⁺ and the polyphenol drug ChA in the tumor microenvironment, realizing the combined chemotherapy/chemodynamic kinetics in the treatment of tumors. Importantly, the release of Cu²⁺ and ChA can drive the cascade reaction, which can disturb redox homeostasis by producing reactive oxygen species (ROS) and depleting GSH, and induce pyroptosis and make tumor cells more sensitive to cuproptosis. Furthermore, pyroptosis and cuproptosis can evoke immunogenic cell death (ICD) and release damage-associated molecular patterns (DAMPs), stimulating dendritic cells (DCs) to mature and activate CD8⁺ T cells. It is encouraging that ChA-Cu NPs can reprogram TIME to achieve significant tumor growth inhibition.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"384 ","pages":"Article 113941"},"PeriodicalIF":10.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144238136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Affinity-based controlled release of interleukin-4 from scaffolds via biotin-streptavidin interactions for immunomodulation","authors":"Victoria A. Nash,&nbsp;Juan F. Cortes-Troncoso,&nbsp;Phoebe E. Chua,&nbsp;Kara L. Spiller","doi":"10.1016/j.jconrel.2025.113943","DOIUrl":"10.1016/j.jconrel.2025.113943","url":null,"abstract":"<div><div>Immunomodulatory cytokines like interleukin-4 (IL-4) can modulate host immune cell behavior to improve tissue integration, but versatile strategies for modifying complex biomaterials to control the release of such cytokines are limited. Bioconjugation strategies using biotin-avidin interactions offer a promising approach since biotin can be conjugated to proteins, biomaterials, and even cells, without compromising their function. Although it is known that conjugation of biotin to large biomolecules reduces its binding affinity for avidin and avidin variants, the potential to control the release of biotinylated molecules by leveraging these changes in affinity interactions has not been thoroughly investigated. Moreover, the effects of biotin and avidin variants on innate immunity are poorly understood. Therefore, the goals of this study were to determine if biotin-avidin interactions could be manipulated to control the release of IL-4 from biomaterials and to investigate the subsequent effects on primary human macrophage phenotype. First, we characterized the effects of soluble biotin, avidin, and avidin variants, streptavidin and CaptAvidin, on the phenotype of primary human macrophages from 8 different donors using RNA sequencing, finding that CaptAvidin influenced macrophage gene expression much more than the other variants. Then, after evaluating how bioconjugation parameters influenced biotin density and avidin variant binding to porous gelatin scaffolds, we found that biotin-avidin affinity interactions sustained the release of biotinylated IL-4 (bIL-4) from biotinylated and desthiobiotinylated scaffolds bound with either avidin or streptavidin for up to 14 days in vitro. Finally, we measured the response of primary human macrophages from 5 donors to the bIL-4-releasing scaffolds, finding an increase in reparative macrophage phenotype gene expression when bIL-4 was released via biotin-streptavidin interactions compared to scaffolds that relied solely on desorption-based release. These results highlight how biotin-streptavidin interactions can be leveraged for controlled release to achieve an immunomodulatory drug delivery system.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"384 ","pages":"Article 113943"},"PeriodicalIF":10.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144238140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in near-infrared responsive functional nanocomposites for bioimaging and antitumor research","authors":"Juan Wang ,&nbsp;Xing Gao ,&nbsp;Lei Feng ,&nbsp;Deliang Zhang ,&nbsp;Shuhua Lv ,&nbsp;Xiaoyin Li ,&nbsp;Qingjia Liu ,&nbsp;Dongkun Yu ,&nbsp;Miaomiao Xing ,&nbsp;Dongrun Li ,&nbsp;Lulu Suo ,&nbsp;Hongyu Mou ,&nbsp;Jibin Song","doi":"10.1016/j.jconrel.2025.113904","DOIUrl":"10.1016/j.jconrel.2025.113904","url":null,"abstract":"<div><div>Malignant tumors endanger human health, and their characteristics make treatment difficult. Near-infrared (NIR) light has become an ideal choice for biotherapy because it offers good penetrability and low damage. In recent years, NIR-based photothermal therapy, photodynamic therapy, photochemotherapy, and multimodal combination therapy have been developing rapidly, and the corresponding functional nanomaterials have been emerging. This review summarizes advances in NIR-triggered functional nanomaterials in tumor therapy, involving therapeutic reagent applications and synergistic and combined therapeutic systems. The nanomaterials have obvious advantages, such as the excellent performance of photothermal therapy- and photodynamic therapy-related nanomaterials, and multifunctional nanoplatforms capable of integrating multiple therapies. However, they face many challenges, such as the limitations of individual therapies and technical difficulties in the combined applications. In the future, we should focus on optimizing the materials, evaluating the combined therapeutic mechanism, innovating the technology and promoting clinical translation. The nanomaterials are expected to become the key means of clinical oncology treatment, bringing hope to overcome the malignant tumors.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"384 ","pages":"Article 113904"},"PeriodicalIF":10.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144238138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multifunctional delivery strategies and nanoplatforms of SN-38 in cancer therapeutics","authors":"Mercedes Lozano-García ,&nbsp;Emre Dikici ,&nbsp;Daniel Bilbao ,&nbsp;Prasoon Mohan ,&nbsp;Sapna Deo ,&nbsp;Sylvia Daunert","doi":"10.1016/j.jconrel.2025.113937","DOIUrl":"10.1016/j.jconrel.2025.113937","url":null,"abstract":"<div><div>SN-38 or 7-ethyl-10-hydroxycamptothecin is the active metabolite of irinotecan, a widely used chemotherapeutic agent for the treatment of colorectal, pancreatic, lung, breast, gastric, esophageal, hepatocellular, ovarian, brain, leukemia, and lymphoma malignancies. SN-38's antitumoral effect is 100 to 1000 times more potent than that of irinotecan. However, its clinical application is hindered by its poor solubility and chemical instability. To circumvent these challenges and avoid systemic toxicities, such as myelosuppression and diarrhea, several SN-38 delivery systems have been explored. In that regard, formulations based on targeted, controlled and tumor-responsive release of SN-38 have demonstrated to enhance its antitumoral effects and reduce the associated systemic toxicities by limiting the pharmacological activity to the desired tumor location. To this end, prodrugs, conjugates, nanoparticles, dendrimers, or lipid-based strategies for SN-38 delivery have been used. Most recently, multifunctional approaches have emerged as an attractive alternative to develop SN-38 delivery systems, combining several strategies in a single formulation, <em>i.e.</em>, encapsulating nanocarriers, tumor-targeting ligands, stimuli-responsive elements, optimal linkers, drug combinations or bioimaging agents. Despite their therapeutic advantages, multifunctional delivery systems often face challenges concerning their clinical translation compared to conventional therapies, such as biocompatibility, scalability and cost-effectiveness issues. The aim of this work is to review the most recent progress that has been made in the development and assessment of multifunctional delivery systems for cancer treatment.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"384 ","pages":"Article 113937"},"PeriodicalIF":10.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal nanoparticles co-delivering bevacizumab and dichloroacetate for dual targeting of neoangiogenesis and hyperglycolysis in glioblastoma treatment","authors":"Catarina Pacheco ,&nbsp;Olaya de Dios ,&nbsp;Maria Angeles Ramiréz-González ,&nbsp;Cláudia Martins ,&nbsp;Sílvia L. Fialho ,&nbsp;Fátima Baltazar ,&nbsp;Bruno M. Costa ,&nbsp;Pilar Sánchez-Gómez ,&nbsp;Bruno Sarmento","doi":"10.1016/j.jconrel.2025.113931","DOIUrl":"10.1016/j.jconrel.2025.113931","url":null,"abstract":"<div><div>Glioblastoma (GBM) is a virtually incurable primary brain tumor, characterized by aggressive proliferation and sustained angiogenesis. The current anti-angiogenic treatment with systemically administered bevacizumab fails to increase patient survival. Encapsulation of bevacizumab into polymeric nanoparticles has shown promise in improving drug brain bioavailability after intranasal administration. Nevertheless, therapeutic efficacy remains limited by tumor cells adopting a hyperglycolytic metabolism. Here, we optimized BDNP, a multidrug formulation for GBM treatment, by co-entrapment of the anti-angiogenic bevacizumab and the glycolysis inhibitor dichloroacetate into poly(lactic-<em>co</em>-glycolic) acid nanoparticles. We then confirmed BDNP therapeutic potential through a series of <em>in vitro</em> and <em>in vivo</em> assays. BDNP preserved bevacizumab functionality, effectively inhibiting chorioallantoic membrane vascularization and endothelial cell angiogenesis fueled by GBM cell lines or patient-derived neurospheres. Moreover, BDNP successfully prevented the ∼3-fold increase in lactate production triggered by bevacizumab. Surface decoration with a CD147-targeting peptide increased BDNP retention in tumor cells <em>in vitro</em> by ∼10-fold, though it did not significantly improve brain accumulation in a U-251MG GBM mouse model. Regardless of decoration, nanoparticles reached and accumulated in animals' brains after intranasal administration. Intranasal administration of BDNP significantly improved a GBM mouse model survival, with no evidence of toxicity. A similar trend was observed in mice bearing patient-derived neurospheres. These findings highlight BDNP as a promising strategy for GBM therapy and establish valuable protocols for developing and validating novel multidrug nanoparticles, especially for antibodies and small molecule cocktails.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"384 ","pages":"Article 113931"},"PeriodicalIF":10.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing delivery in a multivalent subunit influenza vaccine using mixed polymeric microparticle degradation rates","authors":"Erik S. Pena ,&nbsp;Luis Ontiveros-Padilla ,&nbsp;Nicole R. Lukesh ,&nbsp;Grace L. Williamson ,&nbsp;Connor T. Murphy ,&nbsp;Dylan A. Hendy ,&nbsp;John A. Roque III ,&nbsp;Michael A. Carlock ,&nbsp;Ted M. Ross ,&nbsp;Kristy M. Ainslie ,&nbsp;Eric M. Bachelder","doi":"10.1016/j.jconrel.2025.113936","DOIUrl":"10.1016/j.jconrel.2025.113936","url":null,"abstract":"<div><div>The influenza virus continues to impose a significant yearly burden on society due to the variable efficacy of seasonal vaccines. Further strains like H5N1, that are not included in the seasonal influenza vaccine, may spill over from animal reservoirs and more significantly impact human health. A broadly acting subunit vaccine can offer protection across multiple strains but would have low immunogenicity without an adjuvant, which are currently limited and require delivery systems to mitigate side effects. Further, antigen delivery can be enhanced with carrier systems to provide dose sparing, and thermostability. This study explores acetalated dextran microparticles (Ace-DEX MPs) encapsulating cGAMP and computational optimized broadly reactive antigen (COBRA) hemagglutinin (HA) proteins, to form a multivalent influenza vaccine. Previous research has shown that Ace-DEX cGAMP MPs with varying degradation kinetics can modulate the immune response. Here, we investigate the effects of mixing MPs with different degradation rates to optimize the immune response. Mice vaccinated with slower-degrading cGAMP MPs exhibited higher IgG2a titers and IL-2 producing splenocytes, while those vaccinated with a mix of fast and slow-degrading cGAMP MPs had the highest IFN-γ producing splenocytes. The protection afforded in mice was also shown in ferrets with a H1, H3 and H5 trivalent COBRA formulation adjuvanted by slow degrading cGAMP MPs. Furthermore, using Ace-DEX MPs encapsulating two broadly reactive COBRA H1 and H3 immunogens in particles with fast and slow degradation rates, co-delivered with cGAMP MPs, resulted in less single antigen dominance when the more dominant antigen was encapsulated in the slowest degrading MP. This work underscores the utility of Ace-DEX MPs as a vaccine delivery platform and the impact of MP degradation kinetics on vaccine efficacy.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"384 ","pages":"Article 113936"},"PeriodicalIF":10.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted delivery of engineered extracellular vesicles to simultaneously promote vascularization and muscle regeneration in ischemic limbs","authors":"Ting Zhong ,&nbsp;Ning Gao ,&nbsp;Hong Niu ,&nbsp;Ya Guan ,&nbsp;Jiaxing Wen ,&nbsp;Zhongting Liu ,&nbsp;Jianjun Guan","doi":"10.1016/j.jconrel.2025.113938","DOIUrl":"10.1016/j.jconrel.2025.113938","url":null,"abstract":"<div><div>Critical limb ischemia (CLI) leads to a high rate of limb amputation. Regenerating vasculature and skeletal muscles can save the affected limbs. Therapy using stem cell-derived extracellular vesicles (EVs) has emerged as a promising approach. However, the therapeutic efficacy is limited because EVs were not engineered to simultaneously possess the optimal composition of proangiogenic and promyogenic factors necessary to effectively support the survival, migration, and morphogenesis of endothelial and skeletal muscle cells under ischemic conditions. We discovered that the proangiogenic and promyogenic factors, including miR-126, miR-21, miR-296, miR-182, PDGF-BB, VEGF, bFGF, and HGF, can be concurrently upregulated in EVs derived from human iPSC-derived mesenchymal stem cells (iMSCs) by enhancing either N-cadherin-mediated or RGD-mediated interactions between the cells and matrix. Notably, enhancing N-cadherin interaction was more effective in upregulating these factors. The EVs from enhanced N-cadherin interaction markedly improved survival, migration, and morphogenesis of endothelial cells and myoblasts under the CLI-like conditions. To ensure targeted delivery to ischemic limbs, these EVs were cloaked with platelet membranes modified with an ischemia-homing peptide. Following intravenous delivery in a murine model of ischemic hindlimb, the EVs fully restored blood perfusion within 28 days, and significantly promoted skeletal muscle regeneration. These results underscore the potential of EVs with simultaneously upregulated proangiogenic and promyogenic factors in effectively treating CLI.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"384 ","pages":"Article 113938"},"PeriodicalIF":10.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal injection of cell membrane-coated nanoparticles for retinoblastoma treatment","authors":"Yichi Zhang ,&nbsp;Kaiqi Long ,&nbsp;Ka Yi Lee ,&nbsp;Jia Li ,&nbsp;Shuting Xu ,&nbsp;Kang Chen ,&nbsp;Xi Chen ,&nbsp;Qingyi Dai ,&nbsp;Yifan Lin ,&nbsp;Changyou Zhan ,&nbsp;Weiping Wang","doi":"10.1016/j.jconrel.2025.113939","DOIUrl":"10.1016/j.jconrel.2025.113939","url":null,"abstract":"<div><div>Chemotherapy is a widely adopted treatment for malignant intraocular tumors such as retinoblastoma. However, achieving high delivery efficiency remains challenging due to rapid clearance and lack of targeting specificity. Cancer cell membrane-coated nanoparticles have been extensively reported to exhibit specific affinity to homotypic cancer cells. Here we designed poly (lactic-co-glycolic acid) (PLGA)-based polymeric nanoparticles coated with the plasma membrane of WERI-Rb-1 cells, derived from human retinoblastoma. These nanoparticles showed remarkable affinity to WERI-Rb-1 cells in vitro<em>.</em> Loaded with the FDA-approved chemotherapy drug etoposide, the nanoparticles exhibited excellent antitumor efficacy and excellent biosafety following a single-dose intravitreal injection in vivo. Overall, this work presents a simple yet effective strategy for the treatment of retinoblastoma.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113939"},"PeriodicalIF":10.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}